Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis

Maria N Chamurlieva,Yulia L Korsakova,Tatiana V Korotaeva,Stefka G Radenska-Lopovok

doi:10.25208/vdv1233

Abstract

Biological disease-modifying anti-rheumatic drugs (bDMARDs) are widely used for the treatment of chronic inflammatory rheumatic diseases. Since the introduction of tumor necrosis factor alpha (TNF-) inhibitors, the treatment of rheumatoid arthritis has been revolutionized. The approach of targeting TNF- has considerably improved the success of the treatment of rheumatoid arthritis. Their effectiveness has been extensively proven in randomized clinical trials and in clinical practice. Randomized clinical trials and post-marketing studies proved that patients undergoing TNF- inhibitors therapy are at increased risk of infectious disease, bacterial, viral, fungal, opportunistic, oncology and skin adverse effects such as psoriasis and angiitis of the skin. In this case report drug-induced cutaneous vasculitis developing during TNF- inhibitor (Etanercept) treatment for rheumatoid arthritis is described.

Highlights

Согласие пациента: пациентка добровольно подписала информированное согласие на публикацию персональной медицинской информации в обезличенной форме
Drug-induced cutaneous vasculitis developing during Etanercept treatment for rheumatoid arthritis
The approach of targeting tumor necrosis factor (TNF)-α has considerably improved the success of the treatment of rheumatoid arthritis

Summary

Introduction

Согласие пациента: пациентка добровольно подписала информированное согласие на публикацию персональной медицинской информации в обезличенной форме (именно в этом журнале). Представляем описание клинического случая возникновения лекарственно-индуцированного васкулита кожи на фоне лечения ревматоидного артрита и-ФНО-α этанерцептом. Развитие лекарственно-индуцированного васкулита кожи на фоне лечения ингибитором ФНО-α этанерцептом при ревматоидном артрите. Since the introduction of tumor necrosis factor alpha (TNF-α) inhibitors, the treatment of rheumatoid arthritis has been revolutionized.

Results

Conclusion